Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 11/20 | 0.88 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.59 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.59 |
| ▸ | CCR2 | P41597 | 2/20 | 0.55 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6702373 | 0.94 | CCR3 (1.00) | CCR3ROCK2ROCK1GRIN2BHPGD | |
| SCHEMBL6701940 | 0.89 | CCR3 (1.00) | CCR3ROCK2ROCK1CCR2GRIN2B | |
| SCHEMBL6702434 | 0.86 | CCR3 (1.00) | CCR3ROCK2ROCK1CCR2GRIN2B | |
| SCHEMBL6702253 | 0.82 | CCR3 (1.00) | CCR3ROCK2ROCK1GRIN2B | |
| SCHEMBL6704610 | 0.81 | CCR3 (0.73) | CCR3HPGDNPSR1 | |
| SCHEMBL4579336 | 0.80 | CCR3 (0.74) | CCR3ROCK2ROCK1CCR2GRIN2B | |
| SCHEMBL6704923 | 0.80 | CCR3 (0.67) | CCR3HPGDNPSR1 | |
| SCHEMBL6703876 | 0.79 | CCR3 (1.00) | CCR3 | |
| SCHEMBL6698192 | 0.79 | CCR3 (0.77) | CCR3 | |
| SCHEMBL6704612 | 0.78 | CCR3 (0.71) | CCR3HPGDNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040006107-A1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | KO SOO S (US) | 2004-01-08 | — | — | US | claimed |
| US-6492400-B1 | SUCH AS N-(2,5-DIFLUOROPHENYL)-N'-(2-((4-(PHENYLMETHYL)-1 -PIPERIDINYL)METHYL)PHENYL)UREA; PREVENTION OF ASTHMA AND OTHER ALLERGIC DISEASES | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-12-10 | — | — | US | claimed |
| US-6780857-B2 | FOR TREATMENT AND PREVENTION OF INFLAMMATORY DISEASES SUCH AS ASTHMA AND ALLERGIC DISEASES, AS WELL AS AUTOIMMUNE PATHOLOGIES SUCH AS RHEUMATOID ARTHRITIS AND ATHEROSCLEROSIS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-08-24 | — | — | US | disclosed |
| US-20040006107-A1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | KO SOO S (US) | 2004-01-08 | — | — | US | disclosed |
| US-6492400-B1 | SUCH AS N-(2,5-DIFLUOROPHENYL)-N'-(2-((4-(PHENYLMETHYL)-1 -PIPERIDINYL)METHYL)PHENYL)UREA; PREVENTION OF ASTHMA AND OTHER ALLERGIC DISEASES | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006107-A1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | CCR3, CCR1, CCR10 | CCR3 1/4885ROCK2 4005/4885ROCK1 3460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.